Samuel MBA - Gracell Biotechnologies Chief Officer
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
Insider
Samuel MBA is Chief Officer of Gracell Biotechnologies
| Age | 56 |
| Phone | 86 512 6262 6701 |
| Web | https://www.gracellbio.com |
Gracell Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1941) % which means that it has lost $0.1941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3157) %, meaning that it created substantial loss on money invested by shareholders. Gracell Biotechnologies' management efficiency ratios could be used to measure how well Gracell Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.Gracell Biotechnologies currently holds 182.98 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Gracell Biotechnologies has a current ratio of 7.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Gracell Biotechnologies' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Hoyoung MD | CytomX Therapeutics | 56 | |
| MBA BS | CytomX Therapeutics | 46 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Richard Hameister | Coherus BioSciences | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 34 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Nicole White | Assembly Biosciences | N/A | |
| Karen Kotz | Coherus BioSciences | N/A | |
| CPA MS | Erasca Inc | 55 | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Jonathan MD | Erasca Inc | 53 | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 |
Gracell Biotechnologies Leadership Team
Elected by the shareholders, the Gracell Biotechnologies' board of directors comprises two types of representatives: Gracell Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gracell. The board's role is to monitor Gracell Biotechnologies' management team and ensure that shareholders' interests are well served. Gracell Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gracell Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yili MBA, Chief Officer | ||
| Yajin MD, Chief Officer | ||
| Wei Cao, Chairman Founder | ||
| Wei BM, Chairman Founder | ||
| Samuel MBA, Chief Officer | ||
| Wendy MD, Chief Officer | ||
| Erin Li, Executive Officer |
Gracell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gracell Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Shares Owned By Insiders | 16.39 % | |||
| Shares Owned By Institutions | 63.11 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| Gross Profit | 366 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |